Procept Biorobotics
PRCT
103 hedge funds and large institutions have $1.4B invested in Procept Biorobotics in 2022 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 39 increasing their positions, 32 reducing their positions, and 13 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 3 → 6 (+3)
54% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 13
22% more capital invested
Capital invested by funds: $1.14B → $1.4B (+$256M)
22% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 32
7% more funds holding
Funds holding: 96 → 103 (+7)
3.41% less ownership
Funds ownership: 78.93% → 75.52% (-3.4%)
74% less call options, than puts
Call options by funds: $2.51M | Put options by funds: $9.74M
Top Buyers
| 1 |
BlackRock
New York
|
+$21.7M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$18.8M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$15.2M |
| 4 |
Mirae Asset Global Investments
Seoul,
South Korea
|
+$12.2M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$9.83M |
Top Sellers
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$113M |
| 2 |
CI
CPMG Inc
Dallas,
Texas
|
-$74.3M |
| 3 |
Viking Global Investors
Stamford,
Connecticut
|
-$50.5M |
| 4 |
PA
Perceptive Advisors
New York
|
-$19.4M |
| 5 |
FRA
Frank Rimerman Advisors
Palo Alto,
California
|
-$9.49M |
PRCT Hedge Fund Activity: Q3 2022 in Review
103 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Procept Biorobotics (PRCT) for Q3 2022, worth a combined $1.4B — up 22% from $1.14B a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new PRCT positions and 13 closed out — a net gain of 7 holders — while 39 added to existing stakes and 32 trimmed.
The largest buyer was BlackRock, adding an estimated $21.7M. The largest seller was T. Rowe Price Associates, cutting an estimated $113M.
- 103 institutional investors held Procept Biorobotics (PRCT) as of Q3 2022, up from 96 in Q2 2022.
- Funds reported $1.4B of Procept Biorobotics stock for Q3 2022, up 22% quarter-over-quarter.
- 20 funds opened new Procept Biorobotics positions in Q3 2022 and 13 closed out, a net change of +7 holders.
- The largest Procept Biorobotics buyer in Q3 2022 was BlackRock, an estimated $21.7M added.
- The largest Procept Biorobotics seller in Q3 2022 was T. Rowe Price Associates, an estimated $113M sold.
Based on aggregated 13F filings for Q3 2022.